Page 4 - reflections_dyslipidaemia_newsletter5_2023
P. 4
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #5 2023
Dyslipidaemia
CLICK HERE CLICK HERE
TO READ A COMMENTARY ON THIS FOR THE LINK TO FULL ARTICLE
ARTICLE ALONG WITH A SUMMARY
OF RCTS OF TRIGLYCERIDE-
LOWERING DRUGS AND THEIR
RESULTS ON MACE RISK REDUCTION.
PATHOPHYSIOLOGY
High-density lipoprotein revisited: Biological functions and clinical relevance.
von Eckardstein A, et al. Eur Heart J. 2023 Apr 21;44(16):1394-1407.
High-density lipoprotein (HDL) particles carry a large number of proteins and lipids, but the unique arrangement of these two main
components in different HDL particle subspecies provides insights into understanding its various physiological roles. Previous
research on HDL focused on their possibly protective role in ASCVD. This review article provides an update on the role of HDL in
health and disease, beyond ASCVD, including the major mechanisms of HDL, the consequences of HDL dysfunction, and the clinical
implications of both low HDL-C and very high HDL-C.
HDL-C has long been known as the ‘good cholesterol’, in contrast to LDL-C which is known as the ‘bad cholesterol’, based on
several studies in the 1970s that demonstrated an inverse relationship between HDL-C and the risk of developing coronary heart
disease. More recently, a U-shaped relationship has been revealed between HDL-C levels and several conditions with both low and
extremely high HDL-C levels associated with an increased risk of several pathologies and mortality.
Low HDL-C has been shown to be associated with increased risk of all-cause mortality, ASCVD, infectious disease, mortality from
sepsis, autoimmune disease, cancer, diabetes, and decreased kidney function. Extremely high HDL-C is associated with increased
risk of all-cause mortality, CV mortality, other mortality, infectious disease, and age-related macular degeneration.
TABLE OF CONTENTS
